Clinical Trials Logo

Clinical Trial Summary

The goal of this experimental medicine clinical trial is to test the hypothesis that nitrous oxide inhalation will result in a change in neurocircuit function in healthy controls and in individuals with impulsive aggressive tendencies. The main question aims to answer are: Does Nitrous Oxide normalize brain circuit function in impulsively aggressive individuals 24 hours after inhalation. Participants will undergo a 60 minute inhalation session with 50% Nitrous Oxide (or room air at another session) and then undergo an fMRI scan 24 hours later. Researchers will compare healthy controls and impulsively aggressive individuals to see if Nitrous Oxide can normalize the function of cortico-limbic circuits in the latter group.


Clinical Trial Description

This study is designed to see if inhalation of 50% nitrous oxide (N2O) also known as laughing gas, can normalize cortico-limbic circuit functioning in impulsively aggressive human subjects. If the study results are positive, it would allow further studies of this potential treatment modality for those with recurrent, problematic, impulsive aggressive behavior (Intermittent Explosive Disorder: IED). IED is a disorder in which there are frequent and sudden outbursts of anger (yelling, throwing and breaking things, hitting people) that lead to problems with other people socially or at work. It affects about 4% of the US population lifetime, and does not have any approved treatments. The study will test if N2O can normalize brain activity 24 hours after infusion, in participants with a diagnosis of IED compared with healthy, non-aggressive, controls. This is a double-blinded-randomized study with comparison between groups (controls and IED patients) and comparison for each participant between N2O and placebo (air) inhalation. Participants will receive one type of inhalation 24 hours before undergoing an fMRI. Participants will be randomized to the order in which they receive N2O or air. Participants and study personnel involved in collection of outcome measures will be blinded to the type of inhalation. The study includes up to 7 visits. Visits 1/2 include interviews and questionnaires. At visits 3 and 5, participants receive the N2O or air inhalation. At visits 4 and 6, participants undergo fMRI while completing computer tasks. Visit 7 is to assure data collection is complete. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06118567
Study type Interventional
Source Ohio State University
Contact Jayla Copland, B.A.
Phone 614-327-1707
Email jayla.copland@osumc.edu
Status Recruiting
Phase Phase 2
Start date September 6, 2022
Completion date August 31, 2025

See also
  Status Clinical Trial Phase
Terminated NCT00282165 - Efficacy of a Triptan in the Treatment of Hostility and Aggression Among Convicts With a Psychiatric Treatment Order Phase 4
Not yet recruiting NCT04819230 - A Cognitive Bias Modification RCT for Aggression N/A
Completed NCT02055638 - Safety, Tolerability and Activity of SRX246 in Adults With Intermittent Explosive Disorder Phase 1/Phase 2
Completed NCT00078754 - A Comparison of Fluoxetine and Divalproex for the Treatment of Intermittent Explosive Disorder Phase 2
Completed NCT00399698 - Study to Determine Whether There Are Any Cognitive or Motor Effects From Taking the Medicine Risperidone. Phase 3
Recruiting NCT06118580 - Neural Correlates During Alcohol Intoxication Phase 2
Completed NCT02048241 - Intuniv vs Placebo in the Treatment of Childhood Intermittent Explosive Disorder Phase 4
Not yet recruiting NCT05895513 - Pimavanserin and Aggression and Social Cognition. Phase 2
Terminated NCT03420222 - Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Intermittent Explosive Disorder Phase 2
Recruiting NCT06275607 - Maladaptive Anger Treatment N/A
Completed NCT00127400 - A Pilot Study Comparing the Efficacy of Group Versus Individual Anger Management in Subjects With IED Phase 2
Completed NCT00667212 - Psychotherapy for Intermittent Explosive Disorder Phase 2